CN101062041A - Novel medical function of cucurbitacin - Google Patents
Novel medical function of cucurbitacin Download PDFInfo
- Publication number
- CN101062041A CN101062041A CN 200710011515 CN200710011515A CN101062041A CN 101062041 A CN101062041 A CN 101062041A CN 200710011515 CN200710011515 CN 200710011515 CN 200710011515 A CN200710011515 A CN 200710011515A CN 101062041 A CN101062041 A CN 101062041A
- Authority
- CN
- China
- Prior art keywords
- cucurbitacin
- new medical
- dosage
- medical usage
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 title claims abstract description 62
- LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 150000001904 cucurbitacins Chemical class 0.000 title claims abstract description 51
- PIGAXYFCLPQWOD-UHFFFAOYSA-N dihydrocucurbitacin I Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PIGAXYFCLPQWOD-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 18
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 15
- 238000002347 injection Methods 0.000 claims abstract description 5
- 239000007924 injection Substances 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims abstract description 3
- IHTCCHVMPGDDSL-ZJNDIJRCSA-N Cucurbitacin A Natural products O=C([C@@](O)(C)[C@H]1[C@@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(CO)[C@H]2CC=C2C(C)(C)C(=O)[C@H](O)C[C@@H]12)/C=C/C(OC(=O)C)(C)C IHTCCHVMPGDDSL-ZJNDIJRCSA-N 0.000 claims description 16
- 238000001959 radiotherapy Methods 0.000 claims description 15
- QZJJDOYZVRUEDY-UHFFFAOYSA-N Dihydrocucurbitacin B Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(C)OC(=O)C)C(O)CC3(C)C1CC=C1C2CC(O)C(=O)C1(C)C QZJJDOYZVRUEDY-UHFFFAOYSA-N 0.000 claims description 14
- 201000005264 laryngeal carcinoma Diseases 0.000 claims description 13
- IXQKXEUSCPEQRD-NRNCYQGDSA-N (2S,4R,23E)-2,16beta,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-5,23-dien-25-yl acetate Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)C=CC(C)(C)OC(=O)C)C=C2[C@H]1C[C@H](O)C(=O)C2(C)C IXQKXEUSCPEQRD-NRNCYQGDSA-N 0.000 claims description 12
- -1 suspensoid Substances 0.000 claims description 8
- NDYMQXYDSVBNLL-UHFFFAOYSA-N (9beta,10alpha,16alpha,23E)-25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)C=CC(C)(C)OC(=O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C NDYMQXYDSVBNLL-UHFFFAOYSA-N 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 238000004820 blood count Methods 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241000218999 Begoniaceae Species 0.000 claims description 3
- 241000219193 Brassicaceae Species 0.000 claims description 3
- 241001112083 Elaeocarpaceae Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 241000013557 Plantaginaceae Species 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- PTCAIPUXGKZZBJ-UHFFFAOYSA-N 11-deoxocucurbitacin I Natural products CC12CCC3(C)C(C(C)(O)C(=O)C=CC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PTCAIPUXGKZZBJ-UHFFFAOYSA-N 0.000 claims description 2
- LMJMTWXDWFWZHV-CWJYERATSA-N Cucurbitacin Q Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)/C=C/C(C)(C)OC(=O)C)C=C2[C@H]1C[C@@H](O)[C@@H](O)C2(C)C LMJMTWXDWFWZHV-CWJYERATSA-N 0.000 claims description 2
- 125000002812 cucurbitacin B group Chemical group 0.000 claims description 2
- NISPVUDLMHQFRQ-ILFSFOJUSA-N cucurbitacin I Natural products CC(C)(O)C=CC(=O)[C@](C)(O)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC=C4[C@@H](C=C(O)C(=O)C4(C)C)[C@]3(C)C(=O)C[C@]12C NISPVUDLMHQFRQ-ILFSFOJUSA-N 0.000 claims description 2
- NISPVUDLMHQFRQ-MKIKIEMVSA-N cucurbitacin I Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)/C=C/C(C)(O)C)C=C2[C@H]1C=C(O)C(=O)C2(C)C NISPVUDLMHQFRQ-MKIKIEMVSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 201000002364 leukopenia Diseases 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- UZEAHFLEZWXHCE-UHFFFAOYSA-N 3-iodo-2-methylaniline Chemical compound CC1=C(N)C=CC=C1I UZEAHFLEZWXHCE-UHFFFAOYSA-N 0.000 description 5
- 206010023825 Laryngeal cancer Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 206010023841 laryngeal neoplasm Diseases 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 3
- VVBWBGOEAVGFTN-SYJGCRHZSA-N Cucurbitacin P Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)CCC(C)(O)C)C=C2[C@H]1C[C@@H](O)[C@@H](O)C2(C)C VVBWBGOEAVGFTN-SYJGCRHZSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- VVBWBGOEAVGFTN-UHFFFAOYSA-N dihydrocucurbitacin F Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2CC(O)C(O)C1(C)C VVBWBGOEAVGFTN-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- NDYMQXYDSVBNLL-LAMASETHSA-N (23E)-25-acetyloxy-2,16alpha,20-trihydroxy-9beta-methyl-19-nor-10alpha-lanosta-1,5,23-triene-3,11,22-trione Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)C=CC(C)(C)OC(=O)C)C=C2[C@H]1C=C(O)C(=O)C2(C)C NDYMQXYDSVBNLL-LAMASETHSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 240000009087 Crescentia cujete Species 0.000 description 1
- 235000005983 Crescentia cujete Nutrition 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020633 Hyperglobulinaemia Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 235000009797 Lagenaria vulgaris Nutrition 0.000 description 1
- 241001608711 Melo Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028767 Nasal sinus cancer Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- WTBZNVRBNJWSPF-DZEACCAPSA-N [(e,6r)-6-[(3s,8s,9r,10r,13r,14s,16r,17r)-3,16-dihydroxy-4,4,9,13,14-pentamethyl-2,11-dioxo-3,7,8,10,12,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)/C=C/C(C)(C)OC(=O)C)C=C2[C@H]1CC(=O)[C@@H](O)C2(C)C WTBZNVRBNJWSPF-DZEACCAPSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- IVGSDBLLLAUYTL-UHFFFAOYSA-N cucurbitacin E Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C=C(O)C(=O)C4(C)C)C3(C)CCC12C IVGSDBLLLAUYTL-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- GGKKFLWKWDOYQI-UHFFFAOYSA-N iso-cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(CC(=O)C(O)C4(C)C)C3(C)CCC12C GGKKFLWKWDOYQI-UHFFFAOYSA-N 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000292 leukogenic effect Effects 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100115151A CN101062041B (en) | 2007-05-31 | 2007-05-31 | Novel medical function of cucurbitacin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100115151A CN101062041B (en) | 2007-05-31 | 2007-05-31 | Novel medical function of cucurbitacin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101062041A true CN101062041A (en) | 2007-10-31 |
CN101062041B CN101062041B (en) | 2011-11-16 |
Family
ID=38963458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100115151A Expired - Fee Related CN101062041B (en) | 2007-05-31 | 2007-05-31 | Novel medical function of cucurbitacin |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101062041B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101623286A (en) * | 2009-08-04 | 2010-01-13 | 沈阳药科大学 | Transdermal administration composite containing cucurbitacin-type active ingredient |
CN102038689A (en) * | 2009-10-26 | 2011-05-04 | 沈阳药科大学 | Application of cucurbitacin in preparation of medicaments for treating cough |
CN102188403A (en) * | 2010-03-11 | 2011-09-21 | 江苏润邦药业有限公司 | Cucurbitacin capsules and preparation method thereof |
CN102659889A (en) * | 2012-03-16 | 2012-09-12 | 石河子大学 | Preparation of 23, 24-dihydro-epi-iso-cucurbitacin D and use in antitumor drug thereof |
CN101485665B (en) * | 2008-01-16 | 2013-03-20 | 沈阳药科大学 | Novel medical use of cucurbitacin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1723906A (en) * | 2004-07-19 | 2006-01-25 | 胡才忠 | Cucurbitacine liposome and its prepn. method |
CN1883484B (en) * | 2006-05-30 | 2012-09-12 | 沈阳药科大学 | Novel pharmacological use of cucurbitacine |
CN1919339B (en) * | 2006-06-13 | 2013-01-23 | 沈阳药科大学 | Cucurbitacin nano preparation comprising protein, preparation method and use thereof |
-
2007
- 2007-05-31 CN CN2007100115151A patent/CN101062041B/en not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101485665B (en) * | 2008-01-16 | 2013-03-20 | 沈阳药科大学 | Novel medical use of cucurbitacin |
CN101623286A (en) * | 2009-08-04 | 2010-01-13 | 沈阳药科大学 | Transdermal administration composite containing cucurbitacin-type active ingredient |
CN101623286B (en) * | 2009-08-04 | 2014-06-25 | 沈阳药科大学 | Transdermal administration composite containing cucurbitacin-type active ingredient |
CN102038689A (en) * | 2009-10-26 | 2011-05-04 | 沈阳药科大学 | Application of cucurbitacin in preparation of medicaments for treating cough |
CN102038689B (en) * | 2009-10-26 | 2014-04-09 | 沈阳药科大学 | Application of cucurbitacin in preparation of medicaments for treating cough |
CN102188403A (en) * | 2010-03-11 | 2011-09-21 | 江苏润邦药业有限公司 | Cucurbitacin capsules and preparation method thereof |
CN102659889A (en) * | 2012-03-16 | 2012-09-12 | 石河子大学 | Preparation of 23, 24-dihydro-epi-iso-cucurbitacin D and use in antitumor drug thereof |
Also Published As
Publication number | Publication date |
---|---|
CN101062041B (en) | 2011-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050222258A1 (en) | Pharmaceuticals comprising shikonins as active constituent | |
CN101062041B (en) | Novel medical function of cucurbitacin | |
US20070253980A1 (en) | New pharmaceutical composition from natural materials for regulating immunity, its preparation method and use | |
CN103179967A (en) | Anti-tumor pharmaceutical composition | |
CN101485665B (en) | Novel medical use of cucurbitacin | |
CN101129387A (en) | New medical use of cucurbitacin in treating cancer | |
CN103239488A (en) | Application of crude extract product of Ardisia mamillata Hance | |
CN102133210A (en) | Application of resveratrol in preparing medicament for preventing and treating respiratory syncytial virus infections | |
CN1919339A (en) | Cucurbitacin nano preparation comprising protein, preparation method and use thereof | |
CN104666320A (en) | Application of 3,5,3',4'-trihydroxy-stilbene-3'-b-D-glucoside in preparation of medicines for treating cancers | |
CN101757016A (en) | Medicine composition for treating flu and preparation method thereof | |
CN102225089A (en) | Pharmaceutical composition for treating cancers, pharmaceutical preparation as well as applications and production methods thereof | |
CN111558045A (en) | Medicine composition for treating lung cancer | |
CN110403924A (en) | A kind of pharmaceutical composition and preparation method thereof for treating cutaneous melanoma | |
CN1939311A (en) | Ginseng sapogenin aglycone derivative biological preparation and its usage | |
CN1120002C (en) | Application of ammonium nilrate in pharmaceutical industry, food and health-care product | |
CN101199534B (en) | Anti-tumor function of raw panoxadiol derivative | |
CN103655600A (en) | Drug composition for treating cancers, preparation method and applications | |
CN1834108B (en) | Acanthopanax giraldii Harms compound polysaccharide, preparation technique, uses and its compound polysaccharide composition | |
CN103483187A (en) | 4-oxethyl-2-hydroxyl-6-methyl benzoic acid as well as medicinal composition and application thereof | |
CN115089576B (en) | Application of luteolin and chicoric acid in combination in preparation of breast cancer treatment drugs | |
CN110123825B (en) | Pharmaceutical composition containing demethoxydaunorubicin | |
WO2022222388A1 (en) | Use of l-sorbose in preparation of drug for treating tumors | |
CN109602775B (en) | Application of chicory alcohol extract in preparation of anti-breast cancer drugs | |
CN102335182B (en) | Application of triacetylglucal in medicine preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: DELI WEI (BEIJING) BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20140619 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Deng Yihui Inventor after: Zhang Meixia Inventor after: Wu Ying Inventor after: Wu Baozhen Inventor before: Deng Yihui Inventor before: Zhang Meixia |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: DENG YIHUI ZHANG MEIXIA TO: DENG YIHUI ZHANG MEIXIA WU YING WU BAOZHEN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140619 Address after: 110016 Shenhe province Shenyang District Cultural Road, No. 103, No. Patentee after: SHENYANG PHARMACEUTICAL University Patentee after: DELIWEI (BEIJING)BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: 110016 Shenhe province Shenyang District Cultural Road, No. 103, No. Patentee before: Shenyang Pharmaceutical University |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111116 |
|
CF01 | Termination of patent right due to non-payment of annual fee |